Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 known ✓ | Q99720 | 9/20 | 0.65 |
| ▸ | SLC18A2 known ✓ | Q05940 | 1/20 | 0.65 |
| ▸ | MAOA known ✓ | P21397 | 1/20 | 0.52 |
| ▸ | SLC6A2 known ✓ | P23975 | 1/20 | 0.52 |
| ▸ | SLC6A4 known ✓ | P31645 | 1/20 | 0.52 |
| ▸ | SLC6A3 known ✓ | Q01959 | 1/20 | 0.52 |
| ▸ | TAAR1 | Q96RJ0 | 4/20 | 0.65 |
| ▸ | MEN1 | O00255 | 1/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.57 |
| ▸ | NPC1 | O15118 | 1/20 | 0.57 |
| ▸ | RAB9A | P51151 | 1/20 | 0.57 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.55 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.55 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.55 |
| ▸ | TSHR | P16473 | 1/20 | 0.55 |
| ▸ | LMNA | P02545 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10167781 | 0.98 | SIGMAR1 (0.68) | SIGMAR1TAAR1SLC18A2MEN1KMT2A | |
| SCHEMBL2828912 | 0.98 | SIGMAR1 (0.68) | SIGMAR1TAAR1SLC18A2MEN1KMT2A | |
| Levmetamfetamine SCHEMBL42099 | 0.82 | SIGMAR1 (0.95) | SIGMAR1TAAR1SLC18A2MEN1KMT2A | |
| Methamphetamine SCHEMBL1608168 | 0.82 | SIGMAR1 (0.95) | SIGMAR1TAAR1SLC18A2MEN1KMT2A | |
| Methamphetamine SCHEMBL42098 | 0.82 | SIGMAR1 (0.95) | SIGMAR1TAAR1SLC18A2MEN1KMT2A | |
| Methamphetamine SCHEMBL42100 | 0.82 | SIGMAR1 (0.95) | SIGMAR1TAAR1SLC18A2MEN1KMT2A | |
| Methamphetamine SCHEMBL9114797 | 0.82 | SIGMAR1 (0.95) | SIGMAR1TAAR1SLC18A2MEN1KMT2A | |
| Levmetamfetamine SCHEMBL9114800 | 0.82 | SIGMAR1 (0.95) | SIGMAR1TAAR1SLC18A2MEN1KMT2A | |
| SCHEMBL21243273 | 0.81 | SIGMAR1 (0.73) | SIGMAR1TAAR1SLC18A2MEN1KMT2A | |
| SCHEMBL30624762 | 0.81 | SIGMAR1 (0.71) | SIGMAR1TAAR1SLC18A2MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4122914-B1 | COMPOUND AND METHOD FOR PREPARATION OF LISDEXAMFETAMINE | SCI PHARMTECH INC (TW) | 2023-08-16 | — | — | EP | disclosed |
| EP-4215517-A1 | COMPOUND AND METHOD FOR PREPARATION OF LISDEXAMFETAMINE | SCI Pharmtech Inc. (CN) | 2023-07-26 | — | — | EP | disclosed |
| US-11608312-B1 | Compound and method for preparation of lisdexamfetamine | SCI PHARMTECH INC. (TW) | 2023-03-21 | — | — | US | disclosed |
| US-20230084232-A1 | COMPOUND AND METHOD FOR PREPARATION OF LISDEXAMFETAMINE | SCI PHARMTECH INC. (TW) | 2023-03-16 | — | — | US | disclosed |
| EP-4122914-A1 | COMPOUND AND METHOD FOR PREPARATION OF LISDEXAMFETAMINE | SCI Pharmtech Inc. (CN) | 2023-01-25 | — | — | EP | disclosed |
| US-10544434-B2 | Process for the preparation of lisdexamfetamine and related derivatives | NORAMCO, INC. (US) | 2020-01-28 | — | — | US | disclosed |
| WO-2017003721-A1 | PROCESS FOR THE PREPARATION OF LISDEXAMFETAMINE AND RELATED DERIVATIVES | NORAMCO, INC. (US) | 2017-01-05 | — | — | WO | disclosed |
| US-20160376618-A1 | PROCESS FOR THE PREPARATION OF LISDEXAMFETAMINE AND RELATED DERIVATIVES | NORAMCO, LLC | 2016-12-29 | — | — | US | disclosed |
| US-8614346-B2 | Methods and compositions for preparation of amphetamine conjugates and salts thereof | CAMBREX CHARLES CITY, INC. (US) | 2013-12-24 | — | — | US | disclosed |
| US-20120190880-A1 | METHODS AND COMPOSITIONS FOR PREPARATION OF AMPHETAMINE CONJUGATES AND SALTS THEREOF | BLUE OWL CAPITAL CORPORATION, AS NEW AGENT | 2012-07-26 | — | — | US | disclosed |
| WO-2010148305-A1 | METHODS AND COMPOSITIONS FOR PREPARATION OF AMPHETAMINE CONJUGATES AND SALTS THEREOF | CAMBREX CHARLES CITY, INC. (US) | 2010-12-23 | — | — | WO | disclosed |
| US-7705184-B2 | Method of making amphetamine | CAMBREX CHARLES CITY, INC. (US) | 2010-04-27 | — | — | US | disclosed |
| US-20090292143-A1 | METHOD OF MAKING AMPHETAMINE | CAMBREX CHARLES CITY (US) | 2009-11-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120190880-A1 | METHODS AND COMPOSITIONS FOR PREPARATION OF AMPHETAMINE CONJUGATES AND SALTS THEREOF | PNMT, COMT, DDT | SIGMAR1 981/4885SLC18A2 94/4885MAOA 121/4885 |
| US-10544434-B2 | Process for the preparation of lisdexamfetamine and related derivatives | COMT, MGAM, GAA | SIGMAR1 628/4885SLC18A2 100/4885MAOA 56/4885 |
| US-11608312-B1 | Compound and method for preparation of lisdexamfetamine | COMT, CYP2D6, SLC6A3 | SIGMAR1 893/4885SLC18A2 116/4885MAOA 80/4885 |
| US-20160376618-A1 | PROCESS FOR THE PREPARATION OF LISDEXAMFETAMINE AND RELATED DERIVATIVES | COMT, MGAM, GAA | SIGMAR1 628/4885SLC18A2 100/4885MAOA 56/4885 |
| US-20230084232-A1 | COMPOUND AND METHOD FOR PREPARATION OF LISDEXAMFETAMINE | COMT, CYP2D6, SLC6A3 | SIGMAR1 893/4885SLC18A2 116/4885MAOA 80/4885 |
| US-20090292143-A1 | METHOD OF MAKING AMPHETAMINE | COMT, PNMT, CES2 | SIGMAR1 193/4885SLC18A2 68/4885MAOA 18/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.